LEUVEN, Belgium, Sept. 10, 2013 (GLOBE NEWSWIRE) -- TiGenix (NYSE Euronext:TIG), a leader in the field of cell therapy, announced today that it has been invited to present the results of its Phase IIa study of Cx611 in refractory rheumatoid arthritis in a plenary session of the American College of Rheumatology Annual Meeting on October 29. Furthermore, during the second half of 2013, the company will be present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the first approved cell therapy in Europe, and of the company's proprietary allogeneic stem cell programs. TiGenix's lead product Cx601 is currently in Phase III for perianal fistulas in Crohn's disease patients.
| September 15-18 |
| ICRS 2013 , Izmir, Turkey |
| TiGenix Satellite Symposium - Science & evidence in knee cartilage therapy: "Mind the Gap: Quick Fix vs. Durable Repair" |
| Chair: Tim Spalding (UK) MBBS. FRCS, FRCS Orth. Specialist Knee Surgeon, University Hospitals Coventry and Warwickshire NHS Trust. Honorary Associate Professor, Warwick Medical School, University of Warwick |
| Presenters: Philipp Niemeyer, Department of Orthopaedic Surgery and Traumatology, Freiburg University Hospital, Freiburg, Germany; Peter Verdonk, Professor of Orthopaedics and Traumatology, Ghent University, Belgium |
| Date & time: Tuesday, September 17, 1-2 PM |
| September 17-19 |
| BioPharm America 2013 , Westin Boston Waterfront Hotel , Boston, USA |
| Attendee: Claudia Jimenez, Senior Director Business Development |
| October 2-3 |
| 13th Large & Midcap Event , Palais Brongniart, Paris, France |
| Attendee: Claudia D'Augusta, CFO |
| October 14-16 |
| Stem Cell Meeting on the Mesa , La Jolla, California, USA |
| Presenter: Eduardo Bravo, CEO |
| October 23-25 |
| The World Conference on Regenerative Medicine , Congress Center Leipzig, Germany |
| Presenter: Guido Schopen, VP Medical Affairs & Commercial Operations |
| October 25-28 |
| European Society of Gene and Cell Therapy (ESGCT) Collaborative Congress '13 , Palacio Municipal de Congresos, Madrid, Spain |
| Presenters: Wilfried Dalemans, CTO & María Pascual, VP Clinical Operations and Regulatory Affairs |
| October 25-30 |
| American College of Rheumatology (ACR) Annual Meeting 2013 , San Diego, California, USA |
| Presenter: Dr. José María Álvaro-Gracia, MD, PhD, Head of the Biological Therapies Unit, Hospital Universitario de La Princesa, Madrid, Spain |
| Session Name: ACR Plenary Session III: Discovery 2013 |
| Presentation: Phase Ib/IIa Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients |
| Date & time: Tuesday, October 29, 2013: 11:00 AM-12:30 PM |
| November 4-6 |
| BIO-Europe 2013 , Messe Wien Exhibition and Congress Center, Vienna, Austria |
| Attendee: Claudia Jimenez, Senior Director Business Development |
| November 14 |
| 2nd Edition Belgian Biotech & Pharma Seminar , The Grand Hyatt, New York, USA |
| Attendee: Eduardo Bravo, CEO |
| November 21-24 |
| IFATS meeting , Conrad New York, USA |
| Presenter: Dr. Gonzalez-Argente,MD, Head of Surgery Department, Hospital Universitari Son Espases, Palma, Spain |
| Presentation: Expanded allogeneic adipose-derived stem cells for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter Phase I/IIa clinical trial |
| Date & time: Saturday, November 23: 8:12 AM |
| Presenter: Eleuterio Lombardo, Scientific Director TiGenix |
| Presentation: Intralymphatic administration of adipose mesenchymal stem cells shows therapeutic effect in experimental colitis and arthritis |
| Date & time: Saturday, November 23, 3 PM |
| For more information: |
| Eduardo Bravo |
| Chief Executive Officer |
| eduardo.bravo@tigenix.com |
| Claudia D'Augusta |
| Chief Financial Officer |
| claudia.daugusta@tigenix.com |
| Hans Herklots |
| Director Investor & Media Relations |
| hans.herklots@tigenix.com |
| +32 16 39 60 97 |
About TiGenix
TiGenix NV (NYSE Euronext Brussels:TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com .
Forward-looking information
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
